Investigating the role of NUP50 in neurodegenerative diseases like ALS and Alzheimer's
Official title: NUP50 as a modifier and risk factor for TDP-43 pathology in FTD/ALS
Funded at Mayo Clinic Jacksonville · NIH-10800366 · Data updated 2026-11-12
This study is looking at how a protein called NUP50 influences the behavior of another protein, TDP-43, which is connected to diseases like ALS and Alzheimer's, to find new ways to help treat patients with these conditions.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Jacksonville NIH-funded |
| Lab location | 1 site (Jacksonville, United States) |
| Project start | September 30, 2023 |
| Project end | September 29, 2025 |
| Funding year | 2023 |
| Award (this year) | $430,267 |
| NIH project number | 1R21AG085314-01 |
| Project ID | NIH-10800366 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with ALS, frontotemporal dementia, or Alzheimer's disease.
✕Less likely to help
Patients with neurodegenerative diseases not associated with TDP-43 pathology may not benefit from this research.
What this research studies
This research focuses on understanding how the protein NUP50 affects the mislocalization and accumulation of TDP-43, a protein linked to neurodegenerative diseases such as ALS and Alzheimer's. By studying the relationship between NUP50 and TDP-43 pathology, the research aims to uncover potential therapeutic targets that could help restore normal protein function in affected neurons. The approach involves examining cellular mechanisms and genetic factors that contribute to these diseases, which may lead to new treatment strategies for patients.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve outcomes for patients with ALS and Alzheimer's disease.
How similar studies have gone: Previous studies have shown promising results in understanding the role of nucleoporins in neurodegenerative diseases, indicating that this research builds on established findings.
Where this research is happening
-
Mayo Clinic Jacksonville
Jacksonville, United States Active
Researchers
- Principal investigator: Rossoll, Wilfried — Mayo Clinic Jacksonville
- Study coordinator: Rossoll, Wilfried
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.